The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index; none of the 63 sources its claims cite is checked for support yet.
Induced pluripotency in the context of stem cell expansion bioprocess development, optimization, and manufacturing: a roadmap to the clinic
Open accessAbstract
The translation of laboratory-scale bioprocess protocols and technologies to industrial scales and the application of human induced pluripotent stem cell (hiPSC) derivatives in clinical trials globally presents optimism for the future of stem-cell products to impact healthcare. However, while many promising therapeutic approaches are being tested in pre-clinical studies, hiPSC-derived products currently account for a small fraction of active clinical trials. The complexity and volatility of hiPSCs present several bioprocessing challenges, where the goal is to generate a sufficiently large, high-quality, homogeneous population for downstream differentiation—the derivatives of which must retain functional efficacy and meet regulatory safety criteria in application. It is argued herein that one of the major challenges currently faced in improving the robustness of routine stem-cell biomanufacturing is in utilizing continuous, meaningful assessments of molecular and cellular characteristics from process to application. This includes integrating process data with biological characteristic and functional assessment data to model the interplay between variables in the search for global optimization strategies. Coupling complete datasets with relevant computational methods will contribute significantly to model development and automation in achieving process robustness. This overarching approach is thus crucially important in realizing the potential of hiPSC biomanufacturing for transformation of regenerative medicine and the healthcare industry.
Overview
CoChat Summary
TL;DR
This roadmap argues that robust clinical translation of hiPSC-derived therapies requires integrating continuous molecular and cellular process monitoring with biological and functional assessment data to enable computational modeling, automation, and global process optimization. It highlights biological complexity, bioprocess heterogeneity, and sparse clinical trial disclosure as major barriers, noting that iPSC-derived products remain a small fraction of stem-cell clinical trials.
Key findings
- As of August 2021, only 1.2% of documented stem-cell-derived therapeutic clinical trials in the United States utilized iPSCs, and 0.8% utilized ESCs; the vast majority of pluripotent stem cell trials involved in vitro disease modeling. The paper also cites a need for 10^6–10^12 cells per patient.
- Clinical trial examples in Table 1 show mixed outcomes: allogeneic hESC-derived retinal pigment epithelium was Phase I complete with favorable results, whereas an autologous iPSC-derived RPE trial was halted after 2 patients due to safety concerns and copy-number variations; an iPSC-derived mesenchymal stem cell trial verified short-term safety but confounding factors obscured potential effectiveness.
- The paper argues that process heterogeneity, genetic and epigenetic abnormalities, immunogenicity risk, somatic epigenetic memory, sex differences, and metabolic/gene-regulatory network interactions complicate iPSC manufacturing and downstream product quality.
- It recommends coupling in-process data with multi-omics and functional characterization, and applying machine learning/computational modeling for predictive, closed-loop control of iPSC expansion and differentiation.
Methods
- Narrative review/roadmap, not a primary experimental study; it synthesizes literature and examples to explore challenges and strategies in hiPSC biomanufacturing.
- Uses a table of six clinical trials involving pluripotent stem-cell-derived therapeutics, listing cell type, bioprocess characteristics, manufacturing timeline, characterization strategies, and clinical outcomes/status.
- Discusses bioprocess design considerations such as 2D static scale-out versus 3D suspension scale-up, monitoring and characterization technologies, and integration of process data with computational methods.
Limitations
- The paper states that a lack of public disclosure in most clinical trials makes objective comparison of manufacturing design, monitoring, control, and characterization across trials “near impossible,” with details scarce even when disclosure is provided.
- It states that no standardized requirements exist for systems and protocols despite a CGMP framework, and that minimal quality criteria exist, leading to differing process effectiveness, robustness, and outcomes.
- The text makes evident that this is a conceptual narrative review without systematic search methods or primary data; many Table 1 entries are “not disclosed,” and the recommendations remain aspirational rather than empirically validated.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
0 Valid · 2 Not valid · 38 Not checked · 17 Own results and interpretations
In the paper
“This is represented in the lack of interventional studies using ESCs or iPSCs as the derivational source relative to other cell types85.”
§ Induced pluripotency in the context of stem cell expansion bioprocess development, optimization, and manufacturing: a roadmap to the clinic > Clinical trials and the current state of iPSC-derived therapeutics
What the sources say
- Not checked yetcites [85] Kobold, S. et al. A manually curated database on clinical studies involving cell products derived from human pluripotent stem cells. Stem Cell Rep. 15, 546–555 (2020). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“In cases where public disclosure is provided, details are scarce.”
§ Induced pluripotency in the context of stem cell expansion bioprocess development, optimization, and manufacturing: a roadmap to the clinic > Clinical trials and the current state of iPSC-derived therapeutics
What the sources say
- Not checked yetcites [85] Kobold, S. et al. A manually curated database on clinical studies involving cell products derived from human pluripotent stem cells. Stem Cell Rep. 15, 546–555 (2020). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Available data from interventional clinical trials utilizing PSC-derived therapeutics present mixed results from safety and efficacy standpoints.”
§ Induced pluripotency in the context of stem cell expansion bioprocess development, optimization, and manufacturing: a roadmap to the clinic > Clinical trials and the current state of iPSC-derived therapeutics
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“As of August 2021, only 1.2% of documented stem-cell-derived therapeutic clinical trials in the United States alone utilized iPSCs.”
§ Induced pluripotency in the context of stem cell expansion bioprocess development, optimization, and manufacturing: a roadmap to the clinic > Clinical trials and the current state of iPSC-derived therapeutics
What the sources say
- Not checked yetcites [85] Kobold, S. et al. A manually curated database on clinical studies involving cell products derived from human pluripotent stem cells. Stem Cell Rep. 15, 546–555 (2020). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Further, the vast majority of trials utilizing pluripotent stem cells involve in vitro disease modeling.”
§ Induced pluripotency in the context of stem cell expansion bioprocess development, optimization, and manufacturing: a roadmap to the clinic > Clinical trials and the current state of iPSC-derived therapeutics
What the sources say
- Not checked yetcites [85] Kobold, S. et al. A manually curated database on clinical studies involving cell products derived from human pluripotent stem cells. Stem Cell Rep. 15, 546–555 (2020). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
19 more claims
Create a free account to see all 57 claims and to verify the 63 references still open.
- It may state two separate claims as one. 20
- Probably not a substantial claim. 15
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Embryonic Stem Cell Lines Derived from Human Blastocysts
Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., Marshall, V. S., & Jones, J. M. (1998) · Science · doi:10.1126/science.282.5391.1145 · Cited by 15,926
Epigenetic memory in induced pluripotent stem cells
Kim, K., Doi, A., Wen, B., Ng, K., Zhao, R., Cahan, P., Kim, J., Aryee, M. J., Ji, H., Ehrlich, L. I. R., et al. (2010) · Nature · doi:10.1038/nature09342 · Cited by 2,313
Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation
Malta, T. M., Sokolov, A., Gentles, A. J., Burzykowski, T., Poisson, L., Weinstein, J. N., Kamińska, B., Huelsken, J., Omberg, L., Gevaert, O., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.034 · Cited by 2,180
Autologous Induced Stem-Cell–Derived Retinal Cells for Macular Degeneration
Mandai, M., Watanabe, A., Kurimoto, Y., Hirami, Y., Morinaga, C., Daimon, T., Fujihara, M., Akimaru, H., Sakai, N., Shibata, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608368 · Cited by 1,509
Stem Cell Therapies in Clinical Trials: Progress and Challenges
Trounson, A., & McDonald, C. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.06.007 · Cited by 1,468
Epigenetic plasticity and the hallmarks of cancer
Flavahan, W. A., Gaskell, E., & Bernstein, B. E. (2017) · Science · doi:10.1126/science.aal2380 · Cited by 1,340
Writing, erasing and reading histone lysine methylations
Hyun, K., Jeon, J., Park, K., & Kim, J. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.11 · Cited by 1,250
Pluripotent Stem Cell-Based Cell Therapy—Promise and Challenges
Yamanaka, S. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.09.014 · Cited by 1,213
Induction of Pluripotent Stem Cells From Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2008) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000305204.97355.0d · Cited by 1,174
Research works printed but not linked: 1
- Lavon, N., Zimerman, M. & Itskovitz-Eldor, J. In Advances in Biochemical Engineering/Biotechnology Book Series, ABE 163, 22–37 (2017). Edited by Scheper, T., Zhong, J. Published by Springer-Verlag Berlin Heidelberg NewYork.
Cited by
Suresh Babu, S., Duvvuru, H., Baker, J., Switalski, S., Shafa, M., Panchalingam, K. M., Dadgar, S., Beller, J., & Ahmadian Baghbaderani, B. (2023) · Biotechnology Reports · doi:10.1016/j.btre.2023.e00784 · Cited by 22
“quantity and quality information, cost, process invasiveness, time to results, and sample representation of the population [42].”
Background
Metadata
- Authors
- Colter, J., Murari, K., Biernaskie, J., & Kallos, M. S.
- Affiliations
- University of Calgary (CA)
- Corresponding author
- Kallos, Michael Scott
- Venue
- npj Regenerative Medicine
- Published
- 2021-11-01
- Volume
- 6
- Issue
- 1
- Pages
- 72-72
- ISSN
- 2057-3995 (ISSN-L)
- PMC
- PMC8560749
- OpenAlex
- W3210153660
- Semantic Scholar
- 8bced7b48bdcc8c311342e31bda8dd18644fc378
- Cited by
- 33
- References
- 108
- Citations by year
- 2026: 8 · 2025: 5 · 2024: 7 · 2023: 7 · 2022: 5 · 2021: 1
- FWCI
- 0.51
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- npj Regenerative Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Gouvernement du Canada | Canadian Institutes of Health Research
- Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada
- Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
- Keywords
- human induced pluripotent stem cells, bioprocess scale-up, process optimization, process analytical technology, process modeling, process robustness, clinical translation, regenerative medicine, bioprocess automation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-16, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-16 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Induced pluripotency in the context of stem cell expansion bioprocess development, optimization, and manufacturing: a roadmap to the clinic. https://app.cochat.ai/papers/10.1038/s41536-021-00183-7
- The paper
- Colter, J., Murari, K., Biernaskie, J., & Kallos, M. S. (2021). Induced pluripotency in the context of stem cell expansion bioprocess development, optimization, and manufacturing: a roadmap to the clinic. npj Regenerative Medicine. https://doi.org/10.1038/s41536-021-00183-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.